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Background
HTLV-I is causative agent of Acute T-cell Leukemia
(ATL) and HTLV-I associated myelopathy/tropical spas-
tic paraparesis (HAM/TSP). To date there isn’t an estab-
lished treatment available for HTLV-I infection. Type-I
IFNs are well known for their antiviral, anti proliferative
and immunomodulatory effects. Antiviral mechanism of
these IFNs varies depending on the virus and host type
and could fluctuate between virus entry to its replication
and release. IFN-a 2b is qualified for treatment of Hepa-
titis B and C and some malignancies such as specific
leukemias and lymphomas. There are few clinical trials
indicating type-l IFNs efficacy in HTLV-I infected
patients,[1] nevertheless a few studies have focused on
antiviral mechanism of alpha IFNs on HTLV-I.[2,3]
Here we report the reducing effect of IFN-a 2b
(PDferon
®-B) on released particles of HTLV-I by
HTLV-I transformed MT2 cell line.
Materials and methods
MT2 cells were treated with 1000 U/ml of IFN-a 2b (
PDferon
®-B). 12 and 36 hours post treatment, MT2 cells
were collected and cell lysates were analyzed for expres-
sion of HTLV-I Gag, Tax and HBZ genes by gene specific
primers utilizing real time RT-PCR method .As a repre-
sentative of HTLV-I free particles released in supernate
by MT2 cells, virus Gag gene copy number in supernate
was evaluated at aforementioned hours post treatment.
Results
There was no significant difference in expression of
HTLV-I Gag, Tax and HBZ genes between cell lysates
of treated and untreated MT2 cells at both 12 and 36
hours post treatment. At 12 hours post treatment,
released Virus titer was not changed in supernate of
treated cells while a significant decrease in viral particles
was observed in collected supernate of treated cells at
36 hours after treatment with IFN-a2b.
Conclusion
Our result shows that IFN-a2b (PDferon
®-B) treatment
does not have any effect on expression of both struc-
tural and non structural genes of HTLV-I at 12 and 36
hours of treatment thus Reduction of HTLV-I titer at
the 36
th hour post treatment suggests that IFN-a2b (
PDferon
®-B) does not exert its antiviral effects at viral
transcription level. The significant decrease in viral titer
in supernate by IFN-a 2b ( PDferon
®-B) could be due to
its interfering effect at any posttranscriptional level. Our
results are in accordance with previous studies that have
shown the similar effects of other members of type-l
IFN family such as IFNa2a. [2]The exact mechanism by
w h i c ht h i sI F Nh a se x e r t e di t se f f e c t si sy e tt ob ec l a r i -
fied by details. Outcome of such extended studies would
be of paramount importance in using IFN-a 2b in treat-
ment of HTLV-I infection.
Author details
1Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran
University of Medical Sciences, Tehran, Iran.
2Virology department, Pasteur
Institute of Iran, Tehran, Iran.
Published: 3 October 2011
References
1. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J,
Dianoux L, Zermati Y, Haider JH, Hermine O, de The H: Arsenic trioxide
and interferon-alpha synergize to induce cell cycle arrest and apoptosis 2Virology department, Pasteur Institute of Iran, Tehran, Iran
Full list of author information is available at the end of the article
Hartoonian et al. Retrovirology 2011, 8(Suppl 2):P30
http://www.retrovirology.com/content/8/S2/P30
© 2011 Hartoonian et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.in Human T-cell Lymphotropic Virus Type I transformed cells. Blood 1999,
93:278-283.
2. Xuan Feng NVH, Ratner L: Alpha interferon inhibits humanT-cell leukemia
virus type-l assembly by preventing Gag interation with rafts. J Virol
2003, 77:13389-13395.
3. D’Onofrio , Perno CF, Mazzetti P, Graziani G, Calio R, Bonmassar E:
Depression of early phase of HTLV-I infection in vitro mediated by
human beta-interferon. Br J Cancer 1988, 481-488.
doi:10.1186/1742-4690-8-S2-P30
Cite this article as: Hartoonian et al.: IFN-a2b reduces released particles
of Human T-lymphotropic Virus-I from HTLV-I transformed cell line.
Retrovirology 2011 8(Suppl 2):P30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hartoonian et al. Retrovirology 2011, 8(Suppl 2):P30
http://www.retrovirology.com/content/8/S2/P30
Page 2 of 2